Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06764875 · ClinicalTrials.gov registry record · Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

A Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer, sponsored by AstraZeneca.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 3
Development phase: 840
Enrollment target: 20
Study locations

NCT06764875: Recruiting Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer, sponsored by AstraZeneca.

NCT06764875 is a Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 840 participants, above the 383-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (119% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06764875, a Phase 3 study of Gastroesophageal Junction Adenocarcinoma and HER2-positive Gastric Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status: Phase 3
Development phase: 840 participants
Enrollment target: 20
Study locations

Study Summary

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Primary Outcome

PFS is defined as time from randomization until progression per RECIST v1.1, or death due to any cause.

Conditions Studied

Gastroesophageal Junction Adenocarcinoma HER2-positive Gastric Cancer

Interventions

DRUG Pembrolizumab
DRUG Trastuzumab
DRUG Trastuzumab deruxtecan
DRUG Rilvegostomig
DRUG 5-fluorouracil

Study Locations (20)

California

Research Site - Duarte
Research Site - La Jolla
Research Site - Los Alamitos
Research Site - Los Angeles
Research Site - Santa Monica
Research Site - Solvang
Research Site - Upland
Research Site - Walnut Creek

Illinois

Research Site - Chicago
Research Site - Chicago
Research Site - Evanston
Research Site - Hinsdale
Research Site - Niles

Florida

Research Site - Jacksonville
Research Site - Orlando

Alaska

Research Site - Anchorage

Arizona

Research Site - Phoenix

Colorado

Research Site - Aurora

Georgia

Research Site - Marietta

Indiana

Research Site - Dyer

Trial Details

Field	Value
Enrollment Target	840 participants
Start Date	2025-03-01
Est. Completion	2030-12-09
Phase	Phase 3

AstraZeneca

1,285 total trials

What NCT06764875 shows while recruiting

NCT06764875 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, above the 383-participant average among 40 other Gastroesophageal Junction Adenocarcinoma trials with a reported enrollment target (119% higher).

The record links to 2 conditions, with Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT06764875 names 20 study sites across 8 states, led by California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT06764875 about?

NCT06764875 is a clinical study titled "A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer". This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or...

What is the current status of trial NCT06764875?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2025-03-01. Estimated completion is 2030-12-09.

What conditions does trial NCT06764875 study?

This clinical trial studies the following conditions: Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer.

What interventions are being tested in trial NCT06764875?

The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Trastuzumab deruxtecan (DRUG), Rilvegostomig (DRUG), 5-fluorouracil (DRUG).

Who is sponsoring clinical trial NCT06764875?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06764875 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroesophageal Junction Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06764875's enrollment target sits among peer trials

840 8th of 40 higher than 33 of 40 other Gastroesophageal Junction Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastroesophageal Junction Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06764875, the US trial registry maintained by the National Library of Medicine. NCT06764875 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.